Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Johnson & Johnson is presented as the stronger buy-and-hold dividend option, with its 64th consecutive annual dividend increase bringing annual payouts to $5.36 per share and a 2.0% forward yield. Its outlook is tempered by a proposed $5.5 billion ovarian-cancer talc settlement, additional mesothelioma litigation, and $3.7 billion of talc-related reserves as of Q2 2026. Kenvue offers a higher 4.71% yield and trades at roughly 21x earnings, but its $48.7 billion pending cash-and-stock acquisition by Kimberly-Clark creates uncertainty around its standalone dividend outlook.

Analysis

The relevant relative-value setup is not JNJ versus KVUE on headline yield; it is JNJ’s litigation-duration risk versus KMB’s prospective deleveraging and integration risk. A final talc resolution would remove a persistent discount-rate overhang on JNJ and improve management’s flexibility for bolt-on MedTech/M&A, but incremental upside is constrained if its premium multiple already capitalizes a clean legal outcome. Conversely, KVUE’s standalone valuation is now principally a deal-spread instrument, with its yield offering limited informational value if the equity is converted into KMB stock and the combined capital-return policy is reset.

KMB is the underappreciated risk bearer: consumer-health synergies are likely back-end loaded, while leverage, restructuring costs, and retailer bargaining pressure occur immediately. If financing costs remain elevated or regulators require divestitures in overlapping personal-care categories, KMB could face multiple compression before any earnings accretion is visible. This creates a 1-3 month catalyst window around merger approvals, financing disclosures, and pro forma leverage guidance; the 6-18 month outcome depends on whether KMB can protect gross margins while extracting procurement and distribution synergies.

Contrarian view: JNJ’s legal exposure may be more investable than perceived because a definitive settlement converts an unbounded narrative liability into a funded cash-flow item. The greater risk is not the reserve itself but a failed participation threshold or adverse mesothelioma judgments that extend uncertainty, prompting a higher equity risk premium. For KMB/KVUE, consensus may be too focused on closing probability and too optimistic on the post-close dividend capacity of a more levered consumer-staples issuer.

Key Decisions for Investors

• Maintain a modest long JNJ position only below a valuation consistent with a legal-resolution scenario; target a 6-12 month rerating catalyst from settlement finality and MedTech/pharma execution. Falsify on failure to achieve settlement participation, material reserve additions, or a guidance cut to free cash flow.
• Avoid treating KVUE as a standalone income long until the exchange ratio, closing timetable, and combined-company dividend framework are confirmed. For event-driven exposure, buy KVUE only when the annualized deal spread exceeds a pre-set hurdle after adjusting for regulatory duration; exit if approval remedies or financing terms impair consideration.
• Use a KMB short versus a KVUE long only as a tightly hedged merger-arbitrage expression where the announced consideration creates a measurable hedge ratio. Size for a 3-6 month approval horizon; principal risk is a deal break, which would likely pressure KVUE materially while relieving KMB.
• Set alerts for KMB pro forma net leverage, synergy timing, and dividend payout guidance at the next transaction update. If management signals leverage reduction requires slower dividend growth or equity issuance, favor a KMB underweight versus PG or CL for the following 6-18 months.